Foveal thickness reduction after anti-vascular endothelial growth factor treatment in chronic diabetic macular edema | Zendy

Gabriel Willmann | Zendy; Antonio Brunno Nepomuceno | Zendy; Katharina Messias | Zendy; Letícia Barroso | Zendy; Ingrid U. Scott | Zendy; André Messias | Zendy; Rodrigo Jorge | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Foveal thickness reduction after anti-vascular endothelial growth factor treatment in chronic diabetic macular edema

Author(s) -

Gabriel Willmann,

Antonio Brunno Nepomuceno,

Katharina Messias,

Letícia Barroso,

Ingrid U. Scott,

André Messias,

Rodrigo Jorge

Publication year - 2017

Publication title -

international journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 29

eISSN - 2227-4898

pISSN - 2222-3959

DOI - 10.18240/ijo.2017.05.17

Subject(s) - medicine , ophthalmology , ranibizumab , diabetic macular edema , foveal , macular edema , visual acuity , optical coherence tomography , bevacizumab , diabetic retinopathy , diabetes mellitus , surgery , retinal , chemotherapy , endocrinology

To report foveal thickness reduction in eyes with resolution of macular edema and recovery of a foveal depression after one-year of anti-vascular endothelial growth factor (anti-VEGF) therapy for center-involving diabetic macular edema (DME).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research